This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

A new, injectable weight-loss drug has been approved by the U.S. Food and Drug Administration. The agency on Tuesday approved Saxenda (liraglutide) for adults who are obese or for those who are ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication used to support long-term weight loss in adults with obesity, adults with overweight and weight-related health issues, and certain ...

European regulators have recommended an update to the label of Novo Nordisk’s weight loss drug, Saxenda, to include information about the active ingredient’s ability to reduce cardiovascular risk.

Novo Nordisk’s liraglutide is one drug with two names. With last week’s approval of Saxenda, Novo is planning to unveil the second of the two brands in the liraglutide franchise, this one labeled for ...

Now, Cleveland Clinic researchers may have figured out which patients have the best odds of success. Women who take Wegovy to treat obesity have the greatest likelihood of achieving 10% or more weight ...

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non ...

Novo Nordisk announced the launch of Saxenda (liraglutide [rDNA origin]) injection as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult ...

Ozempic may be more expensive and harder to find now that compounded semaglutide isn't available. Here are 9 reputable places ...

Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today ...